Online citations, reference lists, and bibliographies.
← Back to Search

Controlled Release Of Antiproliferative Drugs From Polymeric Systems For Stent Applications And Local Cancer Treatment

Amir Kraitzer, M. Zilberman
Published 2012 · Materials Science

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Restenosis (re-narrowing of the blood vessel wall) and cancer are two different pathologies that have drawn extensive research attention over the years. Antiproliferative drugs such as paclitaxel inhibit cell proliferation and are therefore effective in the treatment of cancer as well as neointimal hyperplasia, which is known to be the main cause of restenosis. Drug-eluting stents (DES) significantly reduce the incidence of in-stent restenosis (ISR), which was once considered a major adverse outcome of percutaneous coronary stent implantations. Localized release of antiproliferative drugs interferes with the pathological proliferation of vascular smooth muscle cells (VSMC), which is the main cause of ISR. Conventional approaches to treating cancer are mainly surgical excision, irradiation, and chemotherapy. In cancer therapy, surgical treatment is usually performed on patients with a resectable carcinoma. An integrated therapeutic approach, such as the addition of a delivery system loaded with an antiproliferative drug at the tumor resection site, is desirable. This will provide a high local concentration of a drug, that is, detrimental to malignant cells which may have survived surgery, thus preventing re-growth and metastasis of the tumor. The present review describes recent advances in systems for controlled release of antiproliferative agents. It describes basic concepts in drug delivery systems and antiproliferative drugs and then focuses on both types of systems: stents with controlled release of antiproliferative agents, and drug-eluting particles and implants for local cancer treatment. The last part of this article is dedicated to our novel drug-eluting composite fiber structures, which can be used as basic stent elements as well as for local cancer treatment.
This paper references
10.1158/0008-5472.CAN-06-1878
A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration.
L. Goldberg (2006)
10.1111/J.1540-8183.2002.TB01091.X
Initial experience with paclitaxel-coated stents.
E. Grube (2002)
10.1136/hrt.2005.060277
Drug eluting stents in 2005
A. Gershlick (2005)
10.1161/CIRCULATIONAHA.108.803528
Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial
G. Stone (2009)
10.1016/S1051-0443(07)61868-5
Thrombogenicity of various endovascular stent types: an in vitro evaluation.
G. Tepe (2002)
10.1583/05-1525.1
Drug-Eluting Biodegradable Poly-D/L-Lactic Acid Vascular Stents: An Experimental Pilot Study
I. Uurto (2005)
10.1161/01.ATV.0000112021.98971.f0
Inhibition of Intimal Thickening in the Rat Carotid Artery Injury Model by a Nontoxic Ras Inhibitor
J. George (2004)
10.2217/fca.11.81
Drug-eluting stents at a crossroads: the good, the bad and the ugly.
W. Nammas (2012)
10.1002/JBM.A.31068
Paclitaxel-loaded composite fibers: microstructure and emulsion stability.
Amir Kraitzer (2007)
10.1146/ANNUREV.PHARMTOX.43.100901.140204
The role of drug transporters at the blood-brain barrier.
A. G. de Boer (2003)
10.1161/01.CIR.0000050367.65079.71
Local Drug Delivery via a Coronary Stent With Programmable Release Pharmacokinetics
A. Finkelstein (2003)
10.1016/J.IJPHARM.2004.05.027
Paclitaxel loaded poly(L-lactic acid) (PLLA) microspheres. II. The effect of processing parameters on microsphere morphology and drug release kinetics.
R. Liggins (2004)
Biodegradable fibers for the controlled release of tetracycline in treatment of peridontal disease ’ ’ , presented at
J. P. English (1987)
10.1007/978-1-4757-0737-3_10
Fibrous Polymers for the Delivery of Contraceptive Steroids to the Female Reproductive Tract
R. Dunn (1981)
10.1016/J.JACC.2005.01.048
Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry.
J. Aoki (2005)
10.1016/J.IJPHARM.2004.06.025
Characterization of perivascular poly(lactic-co-glycolic acid) films containing paclitaxel.
J. Jackson (2004)
10.1114/1.1575756
Expandable Bioresorbable Endovascular Stent. I. Fabrication and Properties
Shih-Horng Su (2004)
10.4244/EIJV3I3A64
Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent).
H. J. Duckers (2007)
10.1093/EURHEARTJ/EHI571
Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation.
S. Hofma (2006)
10.1161/CIRCULATIONAHA.107.693739
Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization
A. Finn (2007)
10.1002/jps.22238
Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro.
Amir Kraitzer (2011)
10.1016/S0168-3659(02)00212-2
Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity.
Cristina Fonseca (2002)
Biodegradable fibers for the controlled release of tetracycline in treatment of peridontal disease’
R. L. Dunn (1987)
10.1007/978-1-4757-0737-3
Controlled Release of Pesticides and Pharmaceuticals
D. Lewis (1981)
10.1097/00004669-199701000-00009
Biomaterials Science: An Introduction to Materials in Medicine
B. Ratner (1996)
Overlie, B
M. B. Leon (2010)
10.1007/s11095-006-9036-z
Electrospun Micro- and Nanofibers for Sustained Delivery of Paclitaxel to Treat C6 Glioma in Vitro
J. Xie (2006)
10.1016/0378-5173(96)04443-2
Solubility and stability of taxol: effects of buffers and cyclodextrins
S. Dordunoo (1996)
10.1212/WNL.30.9.907
Assumptions in the radiotherapy of glioblastoma
F. Hochberg (1980)
10.1016/J.JACC.2005.03.069
The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES).
P. Serruys (2005)
10.1016/S0142-9612(03)00419-8
Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel.
G. Ruan (2003)
10.1016/j.biomaterials.2008.04.002
Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma.
S. Ranganath (2008)
10.1016/J.JACC.2007.06.029
Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
M. Morice (2007)
10.1016/0142-9612(96)85755-3
Mechanisms of polymer degradation and erosion.
A. Göpferich (1996)
10.1097/01.fjc.0000246940.91191.1f
Stent-Based Delivery of Antisense Oligodeoxynucleotides Targeted to the PDGF A-Chain Decreases In-Stent Restenosis of the Coronary Artery
Y. Li (2006)
10.1016/J.SEMCANCER.2004.04.004
Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.
Y. Kloog (2004)
10.1016/0304-3835(94)03614-O
Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid).
H. Burt (1995)
10.1001/jama.299.16.1903
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
G. Stone (2008)
10.1016/J.BIOMATERIALS.2006.07.016
Controlled release of sirolimus from a multilayered PLGA stent matrix.
Xintong Wang (2006)
10.1161/CIRCULATIONAHA.106.621342
Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same?
J. Daemen (2007)
10.1161/01.CIR.99.1.44
Pathology of acute and chronic coronary stenting in humans.
A. Farb (1999)
10.1161/01.RES.86.8.879
Arterial paclitaxel distribution and deposition.
C. Creel (2000)
10.1002/JBM.A.31286
Paclitaxel-eluting composite fibers: drug release and tensile mechanical properties.
M. Zilberman (2008)
10.1097/00005537-200006000-00004
Candidate's Thesis: Polymer Chemotherapy for Head and Neck Cancer
A. Shikani (2000)
Controlled drug delivery : challenges and strategies
K. Park (1997)
10.1016/S0140-6736(02)07679-1
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study
N. Bubnoff (2002)
10.1002/PI.1648
Biodegradable hollow microfibres to produce bioactive scaffolds
L. Lazzeri (2005)
10.3171/JNS.1991.74.3.0441
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
H. Brem (1991)
10.1016/j.colsurfb.2009.06.009
Controlled release of dual drugs from emulsion electrospun nanofibrous mats.
Su Yan (2009)
10.1007/s00701-005-0707-z
Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial
M. Westphal (2005)
10.1111/J.1540-8183.2006.00187.X
Update on bioabsorbable stents: from bench to clinical.
R. Waksman (2006)
10.1016/j.ejps.2009.03.004
Novel farnesylthiosalicylate (FTS)-eluting composite structures.
Amir Kraitzer (2009)
10.1016/S0735-1097(96)00584-0
Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model.
A. Lincoff (1997)
10.1002/JBM.B.20026
Protein-loaded bioresorbable fibers and expandable stents: Mechanical properties and protein release.
M. Zilberman (2004)
10.1016/S0140-6736(09)62127-9
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial
Elvin Kedhi (2010)
10.1016/J.JCONREL.2007.04.022
Release profiles in drug-eluting stents: issues and uncertainties.
S. Venkatraman (2007)
10.1023/A:1016032207246
Development of a Polymeric Surgical Paste Formulation for Taxol
C. Winternitz (2004)
10.1021/MA102574E
Biodegradable Multiblock Poly[N-(2-hydroxypropyl)methacrylamide] via Reversible Addition-Fragmentation Chain Transfer Polymerization and Click Chemistry.
Kui Luo (2011)
Heart (British Cardiac Society
A. H. Gershlick (2005)
10.1016/0300-9629(92)90663-b
Biodegradable polymers as drug delivery systems
L. Zhao (2004)
Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain.
L. Fung (1998)
10.1016/J.JACC.2005.11.092
Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.
J. Kotani (2006)
10.1056/NEJM199408253310801
A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.
P. Serruys (1994)
10.1038/35052535
Gliomagenesis: genetic alterations and mouse models
E. Holland (2001)
10.1016/J.JCONREL.2005.12.012
Paclitaxel releasing films consisting of poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) and their potential as biodegradable stent coatings.
U. Westedt (2006)
10.1002/PI.1086
Biodegradable hollow fibres containing drug-loaded nanoparticles as controlled release systems
G. Polacco (2002)
10.1161/01.CIR.84.3.1426
Clinical trials of restenosis after coronary angioplasty.
J. J. Popma (1991)
10.1161/01.CIR.0000069331.67148.2F
New frontiers in cardiology: drug-eluting stents: Part II.
J. Sousa (2003)
10.1016/j.jacc.2009.08.067
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
M. León (2010)
10.1016/J.BIOMATERIALS.2003.09.055
Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs.
Yuancai Dong (2004)
Coll
M. C. Morice (1299)
10.1016/j.ahj.2008.01.036
Postmarket evaluation of breakthrough technologies.
S. Rao (2008)
10.1161/01.CIR.0000112572.57794.22
Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis
D. Holmes (2004)
10.1016/S0140-6736(08)60415-8
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial
J. Ormiston (2008)
10.1016/j.jcin.2010.07.008
Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
M. León (2010)
10.1161/01.CIR.0000069330.41022.90
New frontiers in cardiology: drug-eluting stents: Part I.
J. Sousa (2003)
10.1016/J.EHJ.2004.06.010
Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent.
F. Vogt (2004)
Interv
G. Tepe (1029)
10.1161/CIRCULATIONAHA.105.591206
Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial
J. Fajadet (2007)
10.1161/01.CIR.0000038984.30279.89
Coated stents for the prevention of restenosis: Part I.
M. Babapulle (2002)
10.1007/s11060-004-2339-1
A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme
S. Limentani (2004)
10.1016/j.jconrel.2007.11.011
Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures.
Amir Kraitzer (2008)
10.1016/J.JACC.2005.06.076
Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients.
J. Aoki (2005)
10.1016/0168-3659(87)90079-4
Biodegradable hollow fibres for the controlled release of hormones
M. Eenink (1987)
Monolithic fibers for controlled delivery of tetracycline’
R. L. Dunn (1982)
10.1016/j.jacc.2008.04.030
Endothelial cell recovery between comparator polymer-based drug-eluting stents.
M. Joner (2008)
10.1056/NEJM199408253310802
A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.
D. Fischman (1994)
10.1016/S0378-5173(99)00087-3
Localized paclitaxel delivery.
A. B. Dhanikula (1999)
10.1016/S0140-6736(09)60325-1
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods
P. W. Serruys (2009)
10.1016/J.JCONREL.2004.04.011
In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices.
Frank Alexis (2004)
10.22203/ECM.V005A01
Biodegradable synthetic polymers for tissue engineering.
P. Gunatillake (2003)
Polymeric Biomaterials
S. Dumitriu (1994)
Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma.
K. Walter (1994)
10.1016/S0142-9612(00)00115-0
The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.
R. Jain (2000)
10.1016/S0168-3659(00)00364-3
Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers.
S. Feng (2001)
10.1016/J.AMJCARD.2007.08.023
Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study.
I. Meredith (2007)
10.1016/S0168-3659(99)00173-X
Biodegradable semi-crystalline comb polyesters influence the microsphere production by means of a supercritical fluid extraction technique (ASES).
A. Breitenbach (2000)
10.1016/S0142-9612(97)00118-X
Review of the biological response to a novel bone cement containing poly(ethyl methacrylate) and n-butyl methacrylate.
P. Revell (1998)
10.1056/NEJMOA067193
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
G. Stone (2007)
10.1016/J.JACC.2006.03.042
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.
M. Joner (2006)
10.1161/01.CIR.0000116202.41966.D4
Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious?
R. Virmani (2004)
10.1161/01.CIR.102.4.399
Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans.
H. Tamai (2000)
10.1161/01.CIR.0000086926.62288.A6
Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions
A. Colombo (2003)
10.1016/S0735-1097(98)00312-X
Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo.
T. Yamawaki (1998)
10.1097/01.RVI.0000058423.01661.57
Drug-eluting stents: potential applications for peripheral arterial occlusive disease.
S. Duda (2003)
10.1201/9780203913338
Tissue Engineering And Novel Delivery Systems
Michael J. Yaszemski (2003)
10.1016/S0168-3659(02)00320-6
A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.
L. Mu (2003)
10.1111/J.1540-8183.2006.00198.X
Polymers, drug release, and drug-eluting stents.
S. Commandeur (2006)
10.1002/JBM.A.20101
Poly(sebacic acid-co-ricinoleic acid) biodegradable carrier for paclitaxel: in vitro release and in vivo toxicity.
A. Shikanov (2004)
Primary brain tumors: review of etiology, diagnosis and treatment.
H. Newton (1994)
10.1016/J.REACTFUNCTPOLYM.2010.10.005
Synthesis of Biodegradable Multiblock Copolymers by Click Coupling of RAFT-Generated HeterotelechelicPolyHPMA Conjugates.
Jiyuan Yang (2011)
Coll
J. Aoki (1670)
10.4244/EIJV3I1A11
Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent.
H. J. Duckers (2007)
10.1056/NEJMOA067722
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.
B. Lagerqvist (2007)
Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits.
N. Alikacem (2000)
10.1016/j.phrs.2008.01.012
The future of drug-eluting stents.
N. Kukreja (2008)
10.1016/S0142-9612(02)00170-9
Why degradable polymers undergo surface erosion or bulk erosion.
F. von Burkersroda (2002)
10.1016/J.CARDIORES.2004.04.029
Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model.
A. J. Carter (2004)
10.1016/j.jacc.2008.01.020
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
M. Krucoff (2008)
10.1161/01.CIR.103.18.2289
Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis
A. Heldman (2001)
10.1007/3-540-45734-8_3
Degradable polymer microspheres for controlled drug delivery
U. Edlund (2002)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar